Brochure: Re-establishment of the right of priority for a Euro-PCT

ARTICLE SUMMARY

If an international patent application was filed after the expiry of the priority year, the right to claim priority will only be recognised by the EPO if a request for re-establishment of the right of priority is allowed under the “all due care” criteria.

authors
Authors
Related Services
Related Industries

If an international patent application was filed after the expiry of the priority year, the right to claim priority will only be recognised by the EPO if a request for re-establishment of the right of priority is allowed under the “all due care” criteria.

A successful restoration of the right to priority in the international phase under the “unintentional” criteria (e.g. by the USPTO as receiving office) is not effective in proceedings before the EPO. Therefore, even if the right of priority has been restored by the receiving office, in many cases it is necessary to file a new request for re-establishment of the EPO on regional phase entry.

The EPO applies a strict procedure to re-establishment matters and typically does not allow new facts to be relied upon once the request for re-establishment has been filed. Typically, detailed evidence regarding the circumstances of the late filing must be submitted at the outset to establish that the all due care criteria has been met.

Depending on the circumstances, the deadline for requesting re-establishment and submitting evidence expires on or shortly after entering the European regional phase. If it is intended to proceed in Europe and re-establish the priority right, action should be taken as soon as possible to make sure the deadline can be met.

Download Brochure

Download the brochure for a summary of the procedure for restoring the priority right of a Euro-PCT application before the EPO.

Thank you.
Your details have been submitted.
Download
Oops! Something went wrong while submitting the form.

Related News

Potter Clarkson launches dedicated women’s health & femtech team

Potter Clarkson launches dedicated women’s health & femtech team

Drug discovery in space: How microgravity is transforming pharmaceutical innovation

Drug discovery in space: How microgravity is transforming pharmaceutical innovation

EU AI Act Article 50: New AI transparency rules

EU AI Act Article 50: New AI transparency rules

Priority patent applications for biotech and chemistry startups

Priority patent applications for biotech and chemistry startups

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

HPV-positive oropharyngeal cancer: prevention to precision treatment

HPV-positive oropharyngeal cancer: prevention to precision treatment

Unlocking the future of cleantech

Unlocking the future of cleantech

Winning at the EPO: Proven specialists in EPO oppositions

Winning at the EPO: Proven specialists in EPO oppositions

See All News
No items found.